With a career spanning more than three decades, Mr. Honigblum boasts extensive experience as a financier for emerging growth companies. His professional journey started as a stockbroker on Wall Street, where he transitioned into investment banking. Over time, he honed his craft at various investment banking boutiques in New York City before co-founding Creation Capital LLC and Creation Capital Advisors with offices in New York and Austin, Texas. The firm specialized in founding and funding breakthrough healthcare technologies. Mr. Honigblum was instrumental in providing early-stage capital for Myriad Genetics (symbol MYGN), the first precision medicine diagnostic company credited with the discovery of BRCA1 and BRCA2 breast cancer genes. Additionally, he was an early-stage investor and financier for Acacia Biosciences, an early informational genomics company that merged with Rosetta Inpharmatics and subsequently acquired by Merck for $620 million. Mr. Honigblum has raised over $500 million for various ventures and has worked in different parts of the world, including London, Italy, Shanghai, China, and Los Angeles. Currently, he resides in Austin, Texas, serving as the Managing Director for FNEX. He holds Series 7, 24, and 63 securities licenses and earned a Bachelor of Arts degree in Economics from the University of Texas at Austin.
Gregg Honigblum